Expertise in
3
conditions

Miguel M. Martin

Madrid, MD, ES 
Expertise in
3
conditions
Madrid, MD, ES 

Overview

Miguel Martin practices practicing medicine in Madrid, Spain.

Mr. Martin is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Febrile Neutropenia, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 122 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Madrid, MD, Spain
Other Locations
Spain
Granada, AN 18071, Spain
Valencia, VC, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer
Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer
Enrollment Status: Unknown
Publish Date: September 29, 2023
Intervention Type: Drug
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Enrollment Status: Completed
Publish Date: September 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

122 Total Publications

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 04, 2026

Frequently Asked Questions about Miguel M. Martin

Is Miguel M. Martin a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Miguel M. Martin is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Miguel M. Martin participate in research or clinical trials?

Yes. Miguel M. Martin has published 122 articles and abstracts on conditions like Breast Cancer. You can view a list of Miguel M. Martin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Martin's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile